文献速递肾小球疾病

抗C反应蛋白自身抗体影响狼疮性肾炎补体激活与临床病程

Autoantibodies against C-Reactive Protein Influence Complement Activation and Clinical Course in Lupus Nephritis.
PubMed 文献 · J Am Soc Nephrol · 2017-05-31

狼疮性肾炎患者常出现抗C反应蛋白(CRP)自身抗体。研究鉴定出CRP氨基酸35-47为主要自身免疫表位,该表位仅在CRP不可逆结构改变形成修饰型/单体CRP(mCRP)后暴露。针对该表位的自身抗体与更严重肾损伤及更差预后相关,并能抑制mCRP与补体因子H的相互作用及增强的辅因子活性。

要点

  • CRP氨基酸35-47是狼疮性肾炎患者抗CRP自身抗体的主要表位。
  • 针对该表位的自身抗体与更严重肾损伤和更差预后相关。
  • mCRP通过该表位与补体因子H结合增强其辅因子活性,而自身抗体抑制此作用。

核心结论

  • CRP氨基酸35-47构成功能性自身免疫表位,mCRP通过调节补体激活参与狼疮性肾炎发病,该表位具诊疗靶向潜力。

研究设计与样本

  • 本研究为实验与临床关联分析,鉴定狼疮性肾炎患者抗CRP自身抗体的主要表位并探讨其功能及临床关联。

主要发现

  • 狼疮性肾炎患者抗CRP自身抗体主要识别CRP氨基酸35-47。
  • 抗氨基酸35-47自身抗体阳性与更严重肾损伤及更差预后相关。
  • ELISA和表面等离子共振显示氨基酸35-47介导mCRP与补体因子H结合并增强其体外辅因子活性。
  • 抗氨基酸35-47自身抗体抑制mCRP与补体因子H的相互作用及增强的辅因子活性。

关键数值与推荐

  • CRP氨基酸35-47为主要自身免疫表位,仅在CRP不可逆结构改变形成mCRP后暴露。

临床怎么用

  • 抗CRP氨基酸35-47自身抗体或可用于狼疮性肾炎患者风险分层。
  • 靶向CRP氨基酸35-47表位可能成为狼疮性肾炎诊疗新策略。

局限性

  • 研究未报告样本量、置信区间及P值等定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoantibodies against the major acute-phase reactant C-reactive protein (CRP) are frequently found in patients with lupus nephritis. Further defining the autoimmune epitopes on CRP may not only improve patient stratification but also, hint at mechanisms of CRP action. Herein, we show that amino acids 35-47 constitute the major epitope recognized by anti-CRP autoantibodies in patients with lupus nephritis. Notably, the presence of autoantibodies against amino acids 35-47 associated with more severe renal damage and predicted worse outcome. This epitope is exposed on CRP only after irreversible structure changes, yielding a conformationally altered form termed modified or monomeric CRP (mCRP). ELISA and surface plasmon resonance assays showed that amino acids 35-47 mediate the interaction of mCRP with complement factor H, an inhibitor of alternative pathway activation, and this interaction greatly enhanced the in vitro cofactor activity of complement factor H. In contrast, autoantibodies against amino acids 35-47 inhibited these actions of mCRP. Our results thus provide evidence for the in vivo generation of mCRP in a human disease and suggest that mCRP actively controls the pathogenesis of lupus nephritis by regulating complement activation. Therefore, amino acids 35-47 constitute a functional autoimmune epitope on CRP that can be targeted therapeutically and diagnostically.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Li QY, Li HY, Fu G, et al. Autoantibodies against C-Reactive Protein Influence Complement Activation and Clinical Course in Lupus Nephritis. J Am Soc Nephrol. 2017. PMID: 28566480. doi:10.1681/ASN.2016070735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。